By Finance Pulse in RCEL —

Avita Medical (RCEL) Receives Buy Rating with $25 Target

Avita Medical (RCEL) initiated as Buy by D. Boral Capital with a $25 price target, highlighting promising clinical results.

A sleek, modern image of a stock market chart with upward trends, symbolizing growth and potential,
Avita Medical (RCEL) Receives Buy Rating with $25 Target

D. Boral Capital initiated coverage of Avita Medical with a Buy rating and $25 price target.

Source